DYN Dyne Therapeutics

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences.

Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, will participate in fireside chats at the following:

  • Stifel 2020 Virtual Healthcare Conference; Monday, November 16, 2020 at 10:00 a.m. ET
  • Jefferies Virtual London Healthcare Conference; Thursday, November 19, 2020 at 7:55 a.m. ET
  • Piper Sandler 32nd Annual Virtual Healthcare Conference; pre-recorded and expected to be available Monday, November 23, 2020

Webcasts and recordings will be available in the Investors & Media section of Dyne’s website at and accessible for 90 days following each presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit , and follow us on ,  and .

Contact:

Dyne Therapeutics

Amy Reilly



857-341-1203

EN
09/11/2020

Underlying

DYNDyne Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dyne Therapeutics

 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for D...

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 -    WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Desi...

August 4, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Re...

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolled to support potential submission for U.S. Accelerated Approval in early 2026 -   - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 ongoing to support potential submission for U.S. Accelerated Approval in late 2026 - WALTHAM, Mass., July 28...

July 28, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Closing of Public Offering of Common Stock...

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exerc...

July 2, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering ...

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable b...

July 1, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $200,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to...

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch